Scholarlink

Introduction <p>This article describes the study rationale and design of the real-world multicenter registry study iCaReMe China.</p> Methods <p>iCaReMe China is a prospective, multicentric, observational registry study aiming to understand the real-world characteristics of patients with type&#xa0;2 diabetes (T2D) and/or hypertension (HTN) [combined chronic kidney disease (CKD)] and/or heart failure (HF) and/or CKD, which may provide some evidence for improving quality of care and outcomes of T2D and/or HTN and/or HF and/or CKD in China. A total of approximately 19,000 subjects will be recruited from 110 participating sites in China. Patients will be enrolled in four disease cohorts based on the primary disease conditions. The primary outcome is to describe the sociodemographic, clinical characteristics, disease management patterns, healthcare resource utilization, and clinical outcomes.</p> Conclusion <p>iCaReMe China aims to describe the real-world characteristics and treatment patterns of patient with T2D and/or HTN (combined CKD) and/or HF and/or CKD. The data from this prospective registry study will facilitate a better understanding of management strategies, the variations across and within different regions, and associated patient outcomes in China.</p> Trial Registration Number <p>ChiCTR2300073764.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Multicenter Registry to Determine Management and Quality of Care of Patients with Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases in China (iCaReMe China)

  • 期刊论文

  • 发表日期：

    2025年2月10日

查看全文
  • Xiaoling Cai,
  • Wenjia Yang,
  • Bo Feng,
  • Qiuhe Ji,
  • Ming Liu,
  • Yanbing Li,
  • Nanwei Tong,
  • Ningling Sun,
  • Minghui Zhao,
  • Linong Ji

摘要

Introduction

This article describes the study rationale and design of the real-world multicenter registry study iCaReMe China.

Methods

iCaReMe China is a prospective, multicentric, observational registry study aiming to understand the real-world characteristics of patients with type 2 diabetes (T2D) and/or hypertension (HTN) [combined chronic kidney disease (CKD)] and/or heart failure (HF) and/or CKD, which may provide some evidence for improving quality of care and outcomes of T2D and/or HTN and/or HF and/or CKD in China. A total of approximately 19,000 subjects will be recruited from 110 participating sites in China. Patients will be enrolled in four disease cohorts based on the primary disease conditions. The primary outcome is to describe the sociodemographic, clinical characteristics, disease management patterns, healthcare resource utilization, and clinical outcomes.

Conclusion

iCaReMe China aims to describe the real-world characteristics and treatment patterns of patient with T2D and/or HTN (combined CKD) and/or HF and/or CKD. The data from this prospective registry study will facilitate a better understanding of management strategies, the variations across and within different regions, and associated patient outcomes in China.

Trial Registration Number

ChiCTR2300073764.